Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the multinational trials to obtain the most precise estimates of the magnitude of treatment effect on measures of dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Noble, Paul W., Albera, Carlo, Bradford, Williamson Z., Costabel, Ulrich, du Bois, Roland M., Fagan, Elizabeth A., Fishman, Robert S., Glaspole, Ian, Glassberg, Marilyn K., Lancaster, Lisa, Lederer, David J., Leff, Jonathan A., Nathan, Steven D., Pereira, Carlos A., Swigris, Jeffrey J., Valeyre, Dominique, King, Talmadge E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697914/
https://www.ncbi.nlm.nih.gov/pubmed/26647432
http://dx.doi.org/10.1183/13993003.00026-2015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697914/
https://www.ncbi.nlm.nih.gov/pubmed/26647432
http://dx.doi.org/10.1183/13993003.00026-2015

Ejemplares similares